Full Text Journal Articles by
Author Marco Bandini

Advertisement

Find full text journal articles






Challenging the dogma of 6 steps for anastomotic urethroplasty in posterior urethral stricture: introducing step 3a.

Pankaj Joshi, Marco Bandini, Francesco Montorsi, Sanjay B Kulkarni,

World J Urol (World journal of urology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Causal contributors to tissue stiffness and clinical relevance in urology.

Laura Martinez-Vidal, Valentina Murdica, Chiara Venegoni, Filippo Pederzoli, Marco Bandini, Andrea Necchi, Andrea Salonia, Massimo Alfano,

Mechanomedicine is an emerging field focused on characterizing mechanical changes in cells and tissues coupled with a specific disease. Understanding the mechanical cues that drive disease progression, and whether tissue stiffening can precede disease development, is crucial in order to define new mechanical biomarkers to improve and develop diagnostic and ... Read more >>

Commun Biol (Communications biology)
[2021, 4(1):1011]

Cited: 0 times

View full text PDF listing >>



Advertisement

Reply by Authors.

Nicholas H Chakiryan, Aaron Dahmen, Marco Bandini, Filippo Pederzoli, Laura Marandino, Maarten Albersen, Eduard Roussel, Yao Zhu, Ding-Wei Ye, Antonio A Ornellas, Mario Catanzaro, Oliver W Hakenberg, Axel Heidenreich, Friederike Haidl, Nick Watkin, Michael Ager, Jad Chahoud, Alberto Briganti, Roberto Salvioni, Francesco Montorsi, Andrea Necchi, Philippe E Spiess,

J Urol (The Journal of urology)
[2021, 206(4):969]

Cited: 0 times

View full text PDF listing >>



Molecular subtyping and immune-gene signatures identify a subset of early bladder tumors as candidates for single-agent immune-checkpoint inhibition.

Andrea Necchi, Daniele Raggi, Andrea Gallina, Marco Bandini, Joep J de Jong, Laura Marandino, Alberto Briganti, Francesco Montorsi, Elai Davicioni, Yair Lotan, Ewan A Gibb,

<h4>Purpose</h4>Clinical high-grade (HG) T1 non-muscle invasive bladder cancer (NMIBC) represents a significant risk to patients, but these patients are not typically offered neoadjuvant therapies, including immune therapy. In this study, we determine whether patients with HG clinical T1 or T2 bladder urothelial carcinoma (UC) have profiles that predict the potential ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study).

Melissa Bersanelli, Sebastiano Buti, Alessio Cortellini, Marco Bandini, Giuseppe Luigi Banna, Filippo Pederzoli, Elena Farè, Daniele Raggi, Patrizia Giannatempo, Ugo De Giorgi, Umberto Basso, Tania Losanno, Daniele Santini, Claudia Mucciarini, Marcello Tucci, Rosa Tambaro, Azzurra Farnesi, Orazio Caffo, Antonello Veccia, Emanuele Naglieri, Alberto Briganti, Giuseppe Procopio, Sandro Pignata, Andrea Necchi,

<h4>Background</h4>Immune checkpoint inhibitors (ICIs) are currently the standard of care for metastatic urothelial cancer (mUC) after the failure of previous platinum-based chemotherapy. The choice of further therapy after ICI progression is a new challenge, and scarce data support it. We aimed to examine the outcomes of mUC patients after progression ... Read more >>

Clin Med Insights Oncol (Clinical Medicine Insights. Oncology)
[2021, 15:11795549211021667]

Cited: 0 times

View full text PDF listing >>



A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02.

Andrea Necchi, Alberto Martini, Daniele Raggi, Vito Cucchiara, Maurizio Colecchia, Roberta Lucianò, Luca Villa, Elio Mazzone, Giuseppe Basile, Simone Scuderi, Filippo Pederzoli, Marco Bandini, Francesco Barletta, Alessandro Larcher, Umberto Capitanio, Andrea Salonia, Alberto Briganti, Jeffrey S Ross, Antonella Messina, Francesco Montorsi,

<h4>Introduction</h4>Advances in neoadjuvant therapy for patients with localized, nonmetastatic, upper tract urothelial carcinoma (UTUC) is needed.<h4>Patients and methods</h4>PURE-02 was a feasibility study enrolling individuals with UTUC, at clinical stage N0M0, with high-risk features according to the modified European Association of Urology definition, based on the presence of either: high-grade disease, ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



High-risk Surgically Resected Renal Cell Carcinoma: Is There a Role for Adjuvant VEGF-TKI Inhibitors?

Giuseppe Fallara, Marco Bandini, Alessandro Larcher, Filippo Pederzoli, Pierre Karakiewicz, Zhe Tian, Alberto Briganti, Andrea Necchi, Andrea Salonia, Roberto Bertini, Francesco Montorsi, Axel Bex, Umberto Capitanio,

The indications for adjuvant vascular endothelial growth factor-tyrosine kinase inhibitor (VEGF-TKI) agents after curative intent nephrectomy for renal cell carcinoma are still a matter of debate. The ASSURE, PROTECT and ATLAS trials have failed to meet their primary end-points. Conversely, S-TRAC has shown a disease free survival (DFS) benefit. To ... Read more >>

Curr Probl Cancer (Current problems in cancer)
[2021, :100759]

Cited: 0 times

View full text PDF listing >>



Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab?

Filippo Pederzoli, Marco Bandini, Daniele Raggi, Laura Marandino, Giuseppe Basile, Massimo Alfano, Renzo Colombo, Andrea Salonia, Alberto Briganti, Andrea Gallina, Francesco Montorsi, Andrea Necchi,

In locally advanced and metastatic malignancies, antibiotic (ATB) therapy has a negative effect on immunotherapy efficacy. Therefore, we aimed to evaluate whether ATB therapy and use of specific ATB classes with concomitant neoadjuvant pembrolizumab affected pathologic complete response (ypT0N0) and relapse-free survival (RFS) for patients with clinical T2-4N0M0 bladder cancer ... Read more >>

Eur Urol (European urology)
[2021, 80(3):319-322]

Cited: 0 times

View full text PDF listing >>



Patterns of Recurrence following Inguinal Lymph Node Dissection for Penile Cancer: Optimizing Surveillance Strategies.

Nicholas H Chakiryan, Aaron Dahmen, Marco Bandini, Filippo Pederzoli, Laura Marandino, Maarten Albersen, Eduard Roussel, Yao Zhu, Ding-Wei Ye, Antonio A Ornellas, Mario Catanzaro, Oliver W Hakenberg, Axel Heidenreich, Friederike Haidl, Nick Watkin, Michael Ager, Jad Chahoud, Alberto Briganti, Roberto Salvioni, Francesco Montorsi, Andrea Necchi, Philippe E Spiess,

<h4>Purpose</h4>Our primary objective is to detail the incidence, site, and timing of penile squamous cell carcinoma (pSCC) recurrence after inguinal lymph node dissection (ILND).<h4>Materials and methods</h4>We performed a retrospective analysis of 551 patients who underwent ILND for pSCC from 2000 to 2017. The primary outcome was pSCC recurrence after ILND. ... Read more >>

J Urol (The Journal of urology)
[2021, 206(4):960-969]

Cited: 0 times

View full text PDF listing >>



Visible-Light Photoredox Catalyzed Dehydrogenative Synthesis of Allylic Carboxylates from Styrenes.

Yang Liu, Simone Battaglioli, Lorenzo Lombardi, Arianna Menichetti, Giovanni Valenti, Marco Montalti, Marco Bandini,

The visible-light photoredox/[Co(III)] cocatalyzed dehydrogenative functionalization of cyclic and acyclic styryl derivatives with carboxylic acids is documented. The methodology enables the chemo- and regioselective allylic functionalization of styryl compounds, leading to allylic carboxylates (32 examples) under stoichiometric acceptorless conditions. Intermolecular as well as intramolecular variants are documented in high yields ... Read more >>

Org Lett (Organic letters)
[2021, 23(11):4441-4446]

Cited: 0 times

View full text PDF listing >>



Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study.

Beat Foerster, Mohammad Abufaraj, Surena F Matin, Mounsif Azizi, Mohit Gupta, Wei-Ming Li, Thomas Seisen, Timothy Clinton, Evanguelos Xylinas, M Carmen Mir, Donald Schweitzer, Andrea Mari, Shoji Kimura, Marco Bandini, Romain Mathieu, Ja H Ku, Gautier Marcq, Georgi Guruli, Markus Grabbert, Anna K Czech, Tim Muilwijk, Armin Pycha, David D'Andrea, Firas G Petros, Philippe E Spiess, Trinity Bivalacqua, Wen-Jeng Wu, Morgan Rouprêt, Laura-Maria Krabbe, Kees Hendricksen, Shin Egawa, Alberto Briganti, Marco Moschini, Vivien Graffeille, Wassim Kassouf, Riccardo Autorino, Axel Heidenreich, Piotr Chlosta, Steven Joniau, Francesco Soria, Phillip M Pierorazio, Shahrokh F Shariat,

<h4>Background</h4>Several groups have proposed features to identify low-risk patients who may benefit from endoscopic kidney-sparing surgery in upper tract urothelial carcinoma (UTUC).<h4>Objective</h4>To evaluate standard risk stratification features, develop an optimal model to identify ≥pT2/N+ stage at radical nephroureterectomy (RNU), and compare it with the existing unvalidated models.<h4>Design, setting, and participants</h4>This ... Read more >>

Eur Urol (European urology)
[2021, 80(4):507-515]

Cited: 0 times

View full text PDF listing >>



Reply to Nicolas Mottet, Olivier Rouviere, and Theodorus H. van der Kwast. Incidental Prostate Cancer: A Real Need for Expansion in Guidelines? Eur Urol Oncol. In press: Incidental Prostate Cancer: An Example of How Important Guidelines Are, Especially When Evidence Is Limited.

Umberto Capitanio, Riccardo Autorino, Marco Bandini, Alberto Briganti, Liang Cheng, Matthew R Cooperberg, Federico Dehò, Andrea Gallina, Laurence Klotz, Brian R Lane, Rodolfo Montironi, Andrea Salonia, Christian Stief, Bertrand Tombal, Francesco Montorsi,

Eur Urol Oncol (European urology oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration.

Praful Ravi, Gregory R Pond, Leonidas N Diamantopoulos, Christopher Su, Ajjai Alva, Rohit K Jain, William P Skelton, Sumati Gupta, Jonathan D Tward, Kathleen M Olson, Parminder Singh, Camilla M Grunewald, Guenter Niegisch, Jae-Lyun Lee, Andrea Gallina, Marco Bandini, Andrea Necchi, Matthew Mossanen, Bradley A McGregor, Catherine Curran, Petros Grivas, Guru P Sonpavde,

<h4>Objectives</h4>To evaluate outcomes of patients achieving a post-treatment pathological stage of <ypT2N0 at radical cystectomy (RC) following neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) to identify an optimal definition of pathological response.<h4>Patients and methods</h4>Patients from 10 international centres who underwent NAC for cT2-4aN0-1 MIBC and achieved <ypT2N0 disease at ... Read more >>

BJU Int (BJU international)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Incidental Prostate Cancer (cT1a-cT1b) Is a Relevant Clinical and Research Entity and Should Be Fully Discussed in the International Prostate Cancer Guidelines.

Umberto Capitanio, Riccardo Autorino, Marco Bandini, Alberto Briganti, Liang Cheng, Matthew R Cooperberg, Federico Dehò, Andrea Gallina, Laurence Klotz, Brian Lane, Rodolfo Montironi, Andrea Salonia, Christian Stief, Bertrand Tombal, Francesco Montorsi,

Eur Urol Oncol (European urology oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab.

Andrea Necchi, Joep J de Jong, Daniele Raggi, Alberto Briganti, Laura Marandino, Andrea Gallina, Marco Bandini, Bashar Dabbas, Elai Davicioni, Umberto Capitanio, Francesco Montorsi, Roland Seiler, Jonathan L Wright, Yair Lotan, Peter C Black, Ewan A Gibb,

<h4>Background</h4>In patients with muscle-invasive urothelial bladder cancer (MIBC), molecular alterations in immunotherapy-resistant tumors found at radical cystectomy (RC) remain largely unstudied.<h4>Objective</h4>To investigate the biology of pembrolizumab-resistant tumors in comparison to an RC cohort treated without any systemic therapy and a cohort of neoadjuvant chemotherapy (NAC)-treated tumors.<h4>Design, setting, and participants</h4>Transcriptome-wide expression ... Read more >>

Eur Urol (European urology)
[2021, 80(2):149-159]

Cited: 0 times

View full text PDF listing >>



Assessing in-hospital morbidity after urethroplasty using the European Association of Urology Quality Criteria for standardized reporting.

Marco Bandini, Guido Barbagli, Riccardo Leni, Giuseppe O Cirulli, Giuseppe Basile, Sofia Balò, Francesco Montorsi, Salvatore Sansalone, Andrea Salonia, Alberto Briganti, Denis Butnaru, Massimo Lazzeri,

<h4>Purpose</h4>To conduct a rigorous assessment of in-hospital morbidity after urethroplasty according with the European Association of Urology (EAU) guidelines for complication reporting.<h4>Methods</h4>We retrospectively (2015-2019) identified 469 consecutive patients receiving urethroplasty (e.g. bulbar urethroplasty with grafts, penile urethroplasty with/without grafts/flaps, Johanson, de novo or revision perineostomy, end-to-end anastomosis, meatoplasty and/or meatotomy) ... Read more >>

World J Urol (World journal of urology)
[2021, :]

Cited: 1 time

View full text PDF listing >>



Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study.

Gautier Marcq, Beat Foerster, Mohammad Abufaraj, Surena F Matin, Mounsif Azizi, Mohit Gupta, Wei-Ming Li, Thomas Seisen, Timothy Clinton, Evanguelos Xylinas, M Carmen Mir, Donald Schweitzer, Andrea Mari, Shoji Kimura, Marco Bandini, Romain Mathieu, Ja H Ku, Georgi Guruli, Markus Grabbert, Anna K Czech, Tim Muilwijk, Armin Pycha, David D'Andrea, Firas G Petros, Philippe E Spiess, Trinity Bivalacqua, Wen-Jeng Wu, Morgan Rouprêt, Laura-Maria Krabbe, Kees Hendricksen, Shin Egawa, Alberto Briganti, Marco Moschini, Vivien Graffeille, Riccardo Autorino, Patricia John, Axel Heidenreich, Piotr Chlosta, Steven Joniau, Francesco Soria, Phillip M Pierorazio, Shahrokh F Shariat, Wassim Kassouf,

<h4>Background</h4>The European Association of Urology risk stratification dichotomizes patients with upper tract urothelial carcinoma (UTUC) into two risk categories.<h4>Objective</h4>To evaluate the predictive value of a new classification to better risk stratify patients eligible for kidney-sparing surgery (KSS).<h4>Design, setting, and participants</h4>This was a retrospective study including 1214 patients from 21 centers ... Read more >>

Eur Urol Focus (European urology focus)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Enantioselective CO2 Fixation Via a Heck-Coupling/Carboxylation Cascade Catalyzed by Nickel.

Alessandro Cerveri, Riccardo Giovanelli, Davide Sella, Riccardo Pedrazzani, Magda Monari, Olalla Nieto Faza, Carlos Silva López, Marco Bandini,

A novel asymmetric nickel-based procedure has been developed in which CO<sub>2</sub> fixation is achieved as a second step of a truncated Heck coupling. For this, a new chiral ligand has been prepared and shown to achieve enantiomeric excesses up to 99 %. The overall process efficiently furnishes chiral 2,3-dihydrobenzofuran-3-ylacetic acids, an ... Read more >>

Chemistry (Chemistry (Weinheim an der Bergstrasse, Germany))
[2021, 27(28):7657-7662]

Cited: 0 times

View full text PDF listing >>



Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand?

Giuseppe Basile, Filippo Pederzoli, Marco Bandini, Daniele Raggi, Andrea Gallina, Andrea Salonia, Alberto Briganti, Francesco Montorsi, Philippe E Spiess, Andrea Necchi,

<h4>Introduction</h4>The standard of care for intermediate- and high-risk non-muscle invasive bladder cancer (NMIBC) patients is transurethral resection of bladder tumor followed by intravesical adjuvant immunotherapy with Bacillus Calmette-Guerin (BCG). However, a non-negligible portion of patients is doomed to fail BCG-therapy and, consequently, undergo radical cystectomy as only treatment option available. ... Read more >>

Urol Oncol (Urologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Re: Francesco Soria, Marco Moschini, David D'Andrea, et al. Comparative Effectiveness in Perioperative Outcomes of Robotic versus Open Radical Cystectomy: Results from a Multicenter Contemporary Retrospective Cohort Study. Eur Urol Focus 2020;6:1233-9.

Francesco Montorsi, Marco Bandini, Andrea Necchi,

Eur Urol Focus (European urology focus)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Revolutionizing care for rare genitourinary tumours.

Andrea Necchi, Filippo Pederzoli, Marco Bandini, Philippe E Spiess,

Nat Rev Urol (Nature reviews. Urology)
[2021, 18(2):69-70]

Cited: 0 times

View full text PDF listing >>



Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer.

Marco Bandini, Jeffrey S Ross, Daniele Raggi, Andrea Gallina, Maurizio Colecchia, Roberta Lucianò, Patrizia Giannatempo, Elena Farè, Filippo Pederzoli, Marco Bianchi, Renzo Colombo, Giorgio Gandaglia, Nicola Fossati, Laura Marandino, Umberto Capitanio, Federico Deho', Siraj M Ali, Russell Madison, Jon H Chung, Andrea Salonia, Alberto Briganti, Francesco Montorsi, Andrea Necchi,

<h4>Background</h4>In the PURE-01 study (NCT02736266), we aimed to evaluate the ability to predict the pathologic complete response (pT0N0) after pembrolizumab by using clinical and tumor biomarkers.<h4>Methods</h4>In an open-label, single-arm, phase 2 study, 3 courses of 200 mg pembrolizumab preceding radical cystectomy were administered in patients with T2-4aN0M0 muscle-invasive bladder cancer. The ... Read more >>

J Natl Cancer Inst (Journal of the National Cancer Institute)
[2021, 113(1):48-53]

Cited: 2 times

View full text PDF listing >>



Re: Hugh Mostafid, Ashish M. Kamat, Siamak Daneshmand, et al. Best Practices to Optimise Quality and Outcomes of Transurethral Resection of Bladder Tumours. Eur Urol Oncol 2021;4:12-9.

Francesco Montorsi, Marco Bandini, Marco Moschini, Federico Dehò, Andrea Gallina,

Eur Urol Oncol (European urology oncology)
[2021, 4(1):126]

Cited: 1 time

View full text PDF listing >>



Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy.

Laura Marandino, Antonella Capozza, Marco Bandini, Daniele Raggi, Elena Farè, Filippo Pederzoli, Andrea Gallina, Umberto Capitanio, Marco Bianchi, Giorgio Gandaglia, Nicola Fossati, Maurizio Colecchia, Patrizia Giannatempo, Gianluca Serafini, Barbara Padovano, Andrea Salonia, Alberto Briganti, Francesco Montorsi, Alessandra Alessi, Andrea Necchi,

<h4>Background</h4>Data regarding the incidence and prognostic impact of immune-related imaging changes, assessed by <sup>18</sup>[F] fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) scan, in patients receiving immune-checkpoint inhibitors (ICIs) are lacking. We relied on the population of patients enrolled in the PURE-01 study to evaluate such changes.<h4>Objective</h4>To evaluate the role of ... Read more >>

Eur Urol Focus (European urology focus)
[2020, :]

Cited: 1 time

View full text PDF listing >>



Targetable gene fusions and aberrations in genitourinary oncology.

Filippo Pederzoli, Marco Bandini, Laura Marandino, Siraj M Ali, Russell Madison, Jon Chung, Jeffrey S Ross, Andrea Necchi,

Gene fusions result from either structural chromosomal rearrangement or aberrations caused by splicing or transcriptional readthrough. The precise and distinctive presence of fusion genes in neoplastic tissues and their involvement in multiple pathways central to cancer development, growth and survival make them promising targets for personalized therapy. In genitourinary malignancies, ... Read more >>

Nat Rev Urol (Nature reviews. Urology)
[2020, 17(11):613-625]

Cited: 8 times

View full text PDF listing >>



Advertisement


Disclaimer

1.0357 s